|Year : 2019 | Volume
| Issue : 1 | Page : 7-21
Antimycobacterial strategies to evade antimicrobial resistance in the nontuberculous mycobacteria
Beverley Cherie Millar, John Edmund Moore
Department of Bacteriology, Northern Ireland Public Health Laboratory, Belfast City Hospital; Centre for Experimental Medicine, Queen's University; School of Biomedical Sciences, Ulster University, Northern Ireland, UK
|Date of Web Publication||12-Mar-2019|
Beverley Cherie Millar
Department of Bacteriology, Northern Ireland Public Health Laboratory, Belfast City Hospital, Lisburn Road, Belfast, BT9 7AD, Northern Ireland
Source of Support: None, Conflict of Interest: None
The nontuberculous mycobacteria (NTM) have recently emerged as important bacterial pathogens of both animals and humans. Of particular, concern is the high level of antimicrobial resistance (AMR) displayed by these organisms, which complicates treatment and potential successful outcomes. This review, therefore, wishes to examine novel compounds and approaches to combatting AMR in the NTMs, specifically examining antimycobacterial (NTM) compounds from plants and venoms, as well as examining synergistic and combination effects with other antimicrobials. Novel and modified drugs including new inhaled drugs are examined, as well as the repurposing of existing drugs for antimycobacterial activity. Many of these novel interventions are at various stages of development, from initial concept through to licensed intervention. The challenge remains to translate these interventions from in vitro laboratory models to effective in vivo interactions. When these are realized, then we will have the opportunity of overcoming NTM AMR, to the benefit of medicine, society, and humanity.
Keywords: Antibiotic resistance, antimicrobial resistance, cystic fibrosis, nitric oxide, non-tuberculous mycobacteria, nontuberculous mycobacteria
|How to cite this article:|
Millar BC, Moore JE. Antimycobacterial strategies to evade antimicrobial resistance in the nontuberculous mycobacteria. Int J Mycobacteriol 2019;8:7-21
|How to cite this URL:|
Millar BC, Moore JE. Antimycobacterial strategies to evade antimicrobial resistance in the nontuberculous mycobacteria. Int J Mycobacteriol [serial online] 2019 [cited 2020 Jan 25];8:7-21. Available from: http://www.ijmyco.org/text.asp?2019/8/1/7/253951
| Introduction|| |
Recently, the nontuberculous mycobacteria (NTMs) have emerged as important human and veterinary pathogens, particularly in respiratory disease. These organisms, sometimes referred to as the atypical mycobacteria or “Mycobacteria Other Than Tuberculosis”, are usually found in water, soil, and other environmental sources and are those mycobacteria which do neither belong to the Mycobacterium tuberculosis complex nor are Mycobacterium leprae. At present, there are 198 species (including synonyms) of Mycobacterium, with standing in nomenclature (http://www.bacterio.net/mycobacterium.html), of which the majority belong to the NTMs. Several key seminal review publications describing NTMs have comprehensively reviewed various aspects of NTM disease pathophysiology, epidemiology, diagnosis, treatment, and clinical management and we guide readers to these sources of information.,,
To date, none of these recent review publications have addressed novel strategies to overcome antimicrobial resistance (AMR) among the NTM organisms, and hence, it was the aim of this review to examine recent developments in overcoming AMR in NTM organisms.
| Antimicrobial Resistance|| |
One aspect to emerge from these publications is that of AMR with the NTM organisms. AMR has now emerged as a global public health crisis, with a variety of organisms, namely the Enterobacteriaceae, Pseudomonas aeruginosa and the mycobacteria, particularly TB., AMR in bacteria may be manifested through several mechanisms, including alteration in cell wall permeability to antibiotics, enzymic degradation of antibiotics, efflux pump mechanisms, mutation in protein synthesis and the organism's ability to uncoil its nucleic acid. [Table 1] summarizes the resistance mechanisms that NTM organisms adopt to evade attack from conventional antibiotic agents.
|Table 1: Action and resistance mechanisms of major classes of conventional antibiotics used to treat nontuberculous mycobacterias|
Click here to view
Given that the NTM organisms are environmental, it is not surprising that they have developed highly elaborate mechanisms of AMR. The environment, particularly the rhizosphere, is a harsh environment for NTMs to survive, due to highly complex inter-strain, inter-species, and inter-genus competition for habitat and nutrition. Therefore, it is advantageous that any organism can ideally perform two important functions in such a scenario, namely (i). evolve AMR mechanisms to evade natural antibiotics being excreted as secondary metabolites by neighboring bacteria, as well as (ii) having the ability to excrete novel natural antibiotic and/or antibiotic-like compounds, to suppress the growth and proliferation of neighbor bacterial organisms. While the NTMs are highly evolved in relation to developing AMR mechanisms, their ability to produce novel antimicrobial compounds is limited whereas paradoxically, another soil organisms, Streptomyces spp., are highly developed in producing novel antimicrobial compounds, but lack sophisticated AMR mechanisms, to evade natural antimicrobials from their neighbors in the soil.
| Mechanisms to Combat Antimicrobial Resistance in Nontuberculous Mycobacteria|| |
The aim of this review is to highlight recent developments which have appeared in the scientific literature within the last 2 years (2017–2018), examining a variety of approaches targeting NTMs.,,,
Medicinal plants are a source of bioactive compounds that can be effective treatments of various diseases globally. Many countries, particularly Mexico, India, Iran, Turkey, and Africa, have a wealth of medicinal plant species which have had a long standing in traditional medicine approaches to the treatment and management of diseases including tuberculosis. Ethnobotanical/pharmacological studies relating of the use of such plants in conjunction with polyherbal medicines, traditionally used for the treatment of tuberculosis are forming the foundations for the identification and in vitro examination of antibacterial properties against NTMs [Table 2].
|Table 2: Pharmacognosy relating to the antimycobacterial activity of plant extracts|
Click here to view
Animal venoms from snakes (terrestrial and sea), scorpions, spiders, honey bees, wasps, and snails, have been investigated and found to be a rich source of natural antimicrobial substances including proteins, amines, bioactive peptides, antimicrobial peptide (AMP), toxins and enzymes, showing activity, by a number of different mechanisms, against many pathogens and more recently, NTMs [Table 3].
Of particular, clinical interest has been the AMPS which are short (10–15 amino acid residues), due to the fact that they are structurally stable, do not easily induce AMR compared to conventional antimicrobials and have shown potent potential in killing bacteria, fungi, viruses, and parasites. AMPs are currently a source of therapeutic potential particularly as they are devoid of hemolytic properties, not toxic to host cells and may be readily synthesized and modified.
Owing to the intrinsic resistance of NTMs to most commonly used antibiotics, such infections are treated by a multidrug regimen as highlighted in the recent “British Thoracic Society Guidelines for the management of non-tuberculous mycobacterial pulmonary disease,” however, treatment issues are further complicated by the ability of Mycobacterium abscessus to develop macrolide resistance on exposure to sub-inhibitory concentrations of the drug  or where other members of the macrolides are used, such as in the case of low-dose azithromycin in the management of patients with cystic fibrosis (CF). Currently, screening for synergistic interactions of approved drugs is an approach which has identified novel in vitro synergistic combinations, with one of the largest studies totaling 180 dual drug combinations against M. abscessus, reported recently by Aziz et al. 2018. [Table 4] summarize several studies which report on potential synergistic and combination effects with other antimicrobials.
|Table 4: Potential synergistic and combination effects with other antimicrobials|
Click here to view
Of interest, has been a recent publication examining the interaction between spices and antibiotic resistance in M. abscessus. In this study, M. abscessus isolates (n = 9 multidrug-resistant clinical isolates from CF patients + 1 reference strain) were examined for their direct susceptibility to 27 spices, as well as the interactive effect of this spice combination to their susceptibility to amikacin and linezolid antibiotic, with standard disk diffusion assay. Five isolates of M. abscessus (5/10; 50%) failed to grow on the spice enriched medium, which included four clinical isolates and the National Culture Type CollectionReference Strain. Of the remaining five isolates which grew on the spice medium, no cultural phenotypic differences were observed, compared to unsupplemented controls. In the case of both amikacin and linezolid, the zone of inhibition increased with the inclusion of the spices. Initially, all isolates of M. abscessus were fully resistant to linezolid (mean zone of inhibition = 0 mm), and growth was to the edge of the antibiotic disk, whereas when in the presence of spices, large zones of inhibition were observed (mean zone of inhibition = 33.3 mm). With amikacin, the mean zone of inhibition increased from 23.2 mm to 32.0 mm, in the presence of spices. These data suggest that the spices were interacting synergistically with the antibiotics, thus making the antibiotic more potent against the bacteria tested. This study is significant as it demonstrates a positive interaction between spices and the conventional antimycobacterial antibiotics, amikacin, and linezolid. Given the burden of AMR to M. abscessus, particularly in a patient with chronic disease such as CF, any food-related innovation that can help maximize the potency of existing antimycobacterial antibiotics is to be encouraged and developed. The specific mechanism as to how spices increase the potency of such antibiotics with M. abscessus now needs to be elucidated, as well as novel food (spice) delivery modalities developed, including novel medicinal foodstuffs or functional foods, that can harness this beneficial effect in vivo.
Due to the urgent need to address the AMR of NTMs, it is important to discover new antimycobacterials, however to date, such drug discovery has been limited, particularly in relation to progression of such novel drugs to clinical trials [Table 5].
|Table 5: The antimycobacterial activity of novel drugs/compounds and modified drugs|
Click here to view
Of particular, interest has been the development of a novel inhaled nonantibiotic therapy, nitric oxide gas formulation, Thiolanox ® (Novoteris, Garden Grove, CA., USA), for the treatment of CF and which is currently in Phase II development (NCT02498535). Interestingly, in Phase I of the clinical study, with CF patients, 160ppm NO inhaled for 30 min, three times daily for five days over two consecutive weeks, indicated that this therapy was safe and significantly reduced the number of various bacteria including M. abscessus, which consequently reduced pulmonary inflammation and increased lung function to levels not commonly observed after antibiotic therapy  [Table 6]. It has been suggested that NO has a multiplicity of targets that are non-organism specific, attributed to its oxidative and nitrosylating effects. NO eradicates microbes by nitrosylating their heme-or thiol-containing essential metabolic proteins which interfere with RNA replication and DNA repair mechanisms, which in turn damages cellular structure and function and modulates the host immune response. Subsequently, an interventional clinical trial is currently in progress to investigate if NO therapy can reduce the NTM bacterial load in the lungs of adults and adolescents with NTM infection (NCT03331445), the preliminary results of which are summarized in [Table 6]. Furthermore, the antibacterial efficacy of a biopolymer, NO-donor BIOC51 (Vast Therapeutics, Chapel Hill, NC., USA) has been demonstrated against NTMs in a mouse in vitro and in vivo model.
|Table 6: Novel Inhaled therapies examined for treatment of nontuberculous mycobacterias|
Click here to view
It is important to consider the fact that NTM can exist both extracellularly in biofilms and intracellularly within macrophages and other host cells, where they can replicate intracellularly. This promotes a challenge when delivering antimicrobial therapy at concentrations which would be effective against NTMs persisting either within biofilms or intracellularly within host cells. Of significant interest has been the development of a liposomal amikacin formulation to address these issues and in particular liposomal inhalation suspension which can be delivered by to target NTM lung diseases. Such delivery mechanisms ensure the delivery of high concentrations of antibiotic directly to the lung along with low systemic concentration in an attempt to prevent cytotoxicity. In vitro and in vivo animal models have shown the ability which this liposomal inhalation suspension has in penetrating NTM biofilms, as well as enhancing amikacin uptake into macrophages. Of major clinical interest has been a multi-centered clinical trial (NCT02344004) which concluded that a single daily nebulization of amikacin liposome inhalation suspension (590 mg), when added to standard guideline-based therapy (GBT) in patients with refractory Mycobacterium avium complex (MAC) lung disease, achieved significantly greater culture conversion by month 6 (defined as three MAC-negative sputum cultures) than GBT alone, along with comparable rates of serious adverse events. These findings further highlight the importance of novel inhaled therapeutic approaches for the treatment of MAC lung disease.
Another approach to tackle the challenge posed by NTM AMR has been the repurposing of existing drugs, namely those that had been approved previously for the treatment of tuberculosis, such as bedaquiline, clofazimine, rifabutin and skin infections, such as tedizolid [Table 7]. Of concern, however, is that fact the resistance mechanisms associated with the MmpL family of proteins have been identified in M. abscessus, in the case of clofazimine and bedaquiline, where clofazimine-resistant strains demonstrated cross resistance to bedaquiline.,,
In addition, in vitro, the antimicrobial effect on NTMs as a result of polypharmacy for the treatment of noninfective conditions has been noted and opens up another avenue to peruse [Table 7].
[Table 8] highlights a number of other approaches which have been investigated in the search for antimycobacterial drugs for NTMs including the examination of existing screening libraries and the examination of bacterial virulence and pathogenic mechanisms with the potential to develop antivirulence therapies and bacteriophage therapy.
Bacteriophage therapy is an interesting approach to consider in the fight against AMR, however to date research in the potential use of such therapy in the case of NTM has been limited with recent focus associated with M. tuberculosis. Indeed, phage therapy although extensively used in Eastern Europe in relation to other pathogenic organisms, is limited elsewhere globally. In general clinical trials, in relation to phage therapy, have been sparse, primarily due to safety concerns relating to the sterility and purity of phages and the potential onset of toxic shock due to the bactericidal effect of phages. Furthermore, regulatory guidelines relating to their therapeutic use require clarification.
In conclusion, AMR in NTM organisms presents significant clinical treatment dilemmas and challenges, for a range of infections associated with NTMs. This review presents a synthesis of novel and innovative approaches, as described in [Table 2], [Table 3], [Table 4], [Table 5], [Table 6], [Table 7], [Table 8], in an attempt to circumvent such AMR problems. These approaches are at various stages of development, from initial concept through to licensed intervention. The challenge remains to translate these interventions from in vitro laboratory models to effective in vivo interactions. When these are realized, then we will have the opportunity of overcoming NTM AMR, to the benefit of medicine, society, and humanity.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Larsson LO, Polverino E, Hoefsloot W, Codecasa LR, Diel R, Jenkins SG, et al.
Pulmonary disease by non-tuberculous mycobacteria – Clinical management, unmet needs and future perspectives. Expert Rev Respir Med 2017;11:977-89.
Primm TP, Lucero CA, Falkinham JO 3rd
. Health impacts of environmental mycobacteria. Clin Microbiol Rev 2004;17:98-106.
Porvaznik I, Solovič I, Mokrý J. Non-tuberculous mycobacteria: Classification, diagnostics, and therapy. Adv Exp Med Biol 2017;944:19-25.
Sheu CC, Lin SY, Chang YT, Lee CY, Chen YH, Hsueh PR, et al.
Management of infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae
: Current evidence and future prospects. Expert Rev Anti Infect Ther 2018;16:205-18.
Nguyen L, Garcia J, Gruenberg K, MacDougall C. Multidrug-resistant Pseudomonas
infections: Hard to treat, but hope on the horizon? Curr Infect Dis Rep 2018;20:23.
Saravanan M, Niguse S, Abdulkader M, Tsegay E, Hailekiros H, Gebrekidan A, et al.
Review on emergence of drug-resistant tuberculosis (MDR and XDR-TB) and its molecular diagnosis in Ethiopia. Microb Pathog 2018;117:237-42.
van Ingen J, Boeree MJ, van Soolingen D, Mouton JW. Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria. Drug Resist Updat 2012;15:149-61.
Huh HJ, Kim SY, Jhun BW, Shin SJ, Koh WJ. Recent advances in molecular diagnostics and understanding mechanisms of drug resistance in nontuberculous mycobacterial diseases. Infect Genet Evol 2018. pii: S1567-1348(18)30784-6.
Luthra S, Rominski A, Sander P. The role of antibiotic-target-modifying and antibiotic-modifying enzymes in Mycobacterium abscessus
drug resistance. Front Microbiol 2018;9:2179.
Wu ML, Aziz DB, Dartois V, Dick T. NTM drug discovery: Status, gaps and the way forward. Drug Discov Today 2018;23:1502-19.
Gupta VK, Kaushik A, Chauhan DS, Ahirwar RK, Sharma S, Bisht D, et al.
Anti-mycobacterial activity of some medicinal plants used traditionally by tribes from Madhya Pradesh, India for treating tuberculosis related symptoms. J Ethnopharmacol 2018;227:113-20.
Famewo EB, Clarke AM, Afolayan AJ. Ethno-medicinal documentation of polyherbal medicines used for the treatment of tuberculosis in Amathole district municipality of the Eastern Cape Province, South Africa. Pharm Biol 2017;55:696-700.
Kazemian H, Heidari H, Yamchi JK, Zandi H, Taji A, Yazdani F, et al
. In vitro
anti-mycobacterial activity of three medicinal plants of Lamiaceae
family. Recent Pat Antiinfect Drug Discov 2018;13:240-5.
Hernández-Sánchez KM, Garduño-Siciliano L, Luna-Herrera J, Zepeda-Vallejo LG, Lagunas-Rivera S, García-Gutiérrez GE, et al.
Antimycobacterial and hypolipemiant activities of Bidens odorata
(Cavanilles). J Ethnopharmacol 2018;222:159-64.
Diop EA, Queiroz EF, Kicka S, Rudaz S, Diop T, Soldati T, et al.
Survey on medicinal plants traditionally used in Senegal for the treatment of tuberculosis (TB) and assessment of their antimycobacterial activity. J Ethnopharmacol 2018;216:71-8.
Rahgozar N, Bakhshi Khaniki G, Sardari S. Evaluation of antimycobacterial and synergistic activity of plants selected based on cheminformatic parameters Iran Biomed J 2018;22:401-7.
Komape NP, Bagla VP, Kabongo-Kayoka P, Masoko P. Anti-mycobacteria potential and synergistic effects of combined crude extracts of selected medicinal plants used by Bapedi traditional healers to treat tuberculosis related symptoms in Limpopo Province, South Africa. BMC Complement Altern Med 2017;17:128.
Nyambuya T, Mautsa R, Mukanganyama S. Alkaloid extracts from Combretum zeyheri
inhibit the growth of Mycobacterium smegmatis
. BMC Complement Altern Med 2017;17:124.
Marini E, Di Giulio M, Magi G, Di Lodovico S, Cimarelli ME, Brenciani A, et al.
Curcumin, an antibiotic resistance breaker against a multiresistant clinical isolate of Mycobacterium abscessus
. Phytother Res 2018;32:488-95.
Rossi GG, Guterres KB, Bonez PC, da Silva Gundel S, Aggertt VA, Siqueira FS, et al.
Antibiofilm activity of nanoemulsions of Cymbopogon flexuosus
against rapidly growing mycobacteria. Microb Pathog 2017;113:335-41.
Bhunu B, Mautsa R, Mukanganyama S. Inhibition of biofilm formation in mycobacterium smegmatis by Parinari curatellifolia
leaf extracts. BMC Complement Altern Med 2017;17:285.
Fomogne-Fodjo MC, Ndinteh DT, Olivier DK, Kempgens P, van Vuuren S, Krause RW, et al.
Secondary metabolites from Tetracera potatoria
stem bark with anti-mycobacterial activity. J Ethnopharmacol 2017;195:238-45.
Matsumura Y, Kitabatake M, Ouji-Sageshima N, Yasui S, Mochida N, Nakano R, et al.
Persimmon-derived tannin has bacteriostatic and anti-inflammatory activity in a murine model of Mycobacterium avium
complex (MAC) disease. PLoS One 2017;12:e0183489.
Coronado-Aceves EW, Gigliarelli G, Garibay-Escobar A, Zepeda RE, Curini M, López Cervantes J, et al.
New isoflavonoids from the extract of Rhynchosia precatoria
(Humb. and bonpl. Ex willd.) DC. and their antimycobacterial activity. J Ethnopharmacol 2017;206:92-100.
Peruč D, Gobin I, Abram M, Broznić D, Svalina T, Štifter S, et al.
Antimycobacterial potential of the juniper berry essential oil in tap water. Arh Hig Rada Toksikol 2018;69:46-54.
Castillo TA, Lemos RA, Pereira JR, Alves JM, Teixeira MF. Mycelial growth and antimicrobial activity of Pleurotus
species (Agaricomycetes). Int J Med Mushrooms 2018;20:191-200.
Bao J, Zhai H, Zhu K, Yu JH, Zhang Y, Wang Y, et al.
Bioactive pyridone alkaloids from a deep-sea-derived fungus Arthrinium
sp. UJNMF0008. Mar Drugs 2018;16. pii: E174.
Maarisit W, Abdjul DB, Yamazaki H, Kato H, Rotinsulu H, Wewengkang DS, et al.
Anti-mycobacterial alkaloids, cyclic 3-alkyl pyridinium dimers, from the Indonesian marine sponge Haliclona
sp. Bioorg Med Chem Lett 2017;27:3503-6.
Abdjul DB, Yamazaki H, Kanno SI, Tomizawa A, Rotinsulu H, Wewengkang DS, et al.
An anti-mycobacterial bisfunctionalized sphingolipid and new bromopyrrole alkaloid from the Indonesian marine sponge Agelas
sp. J Nat Med 2017;71:531-6.
Perumal Samy R, Stiles BG, Franco OL, Sethi G, Lim LHK. Animal venoms as antimicrobial agents. Biochem Pharmacol 2017;134:127-38.
Marques-Neto LM, Trentini MM, das Neves RC, Resende DP, Procopio VO, da Costa AC, et al.
Antimicrobial and chemotactic activity of scorpion-derived peptide, ToAP2, against Mycobacterium massiliensis
. Toxins (Basel) 2018;10. pii: E219.
Trentini MM, das Neves RC, Santos BP, DaSilva RA, de Souza AC, Mortari MR, et al.
Non-disulfide-bridge peptide 5.5 from the scorpion Hadrurus gertschi
inhibits the growth of Mycobacterium abscessus
. Front Microbiol 2017;8:273.
Sala A, Cabassi CS, Santospirito D, Polverini E, Flisi S, Cavirani S, et al.
Novel Naja atra
cardiotoxin 1 (CTX-1) derived antimicrobial peptides with broad spectrum activity. PLoS One 2018;13:e0190778.
Silva JC, Neto LM, Neves RC, Gonçalves JC, Trentini MM, Mucury-Filho R, et al.
Evaluation of the antimicrobial activity of the mastoparan polybia-MPII isolated from venom of the social wasp Pseudopolybia vespiceps testacea
(Vespidae, Hymenoptera). Int J Antimicrob Agents 2017;49:167-75.
das Neves RC, Trentini MM, de Castro e Silva J, Simon KS, Bocca AL, Silva LP, et al.
Antimycobacterial activity of a new peptide polydim-I isolated from neotropical social wasp Polybia dimorpha
. PLoS One 2016;11:e0149729.
Haworth CS, Banks J, Capstick T, Fisher AJ, Gorsuch T, Laurenson IF, et al.
British thoracic society guideline for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). BMJ Open Respir Res 2017;4:e000242.
Aziz DB, Teo JW, Dartois V, Dick T. Teicoplanin – Tigecycline combination shows synergy against Mycobacterium abscessus
. Front Microbiol 2018;9:932.
Schwartz M, Fisher S, Story-Roller E, Lamichhane G, Parrish N. Activities of dual combinations of antibiotics against multidrug-resistant Nontuberculous mycobacteria
recovered from patients with cystic fibrosis. Microb Drug Resist 2018;24:1191-7.
Zhang Z, Lu J, Song Y, Pang Y.In vitro
activity between linezolid and other antimicrobial agents against Mycobacterium abscessus
complex. Diagn Microbiol Infect Dis 2018;90:31-4.
Mukherjee D, Wu ML, Teo JWP, Dick T. Vancomycin and clarithromycin show synergy against Mycobacterium abscessus in vitro
. Antimicrob Agents Chemother 2017;61. pii: e01298-17.
Srivastava S, Deshpande D, Sherman CM, Gumbo T. A 'shock and awe' thioridazine and moxifloxacin combination-based regimen for pulmonary Mycobacterium avium
-intracellulare complex disease. J Antimicrob Chemother 2017;72:i43-i47.
Deshpande D, Srivastava S, Pasipanodya JG, Lee PS, Gumbo T. A novel ceftazidime/avibactam, rifabutin, tedizolid and moxifloxacin (CARTM) regimen for pulmonary Mycobacterium avium
disease. J Antimicrob Chemother 2017;72:i48-i53.
Deshpande D, Srivastava S, Chapagain ML, Lee PS, Cirrincione KN, Pasipanodya JG, et al.
The discovery of ceftazidime/avibactam as an anti-Mycobacterium avium
agent. J Antimicrob Chemother 2017;72:i36-i42.
Kaushik A, Gupta C, Fisher S, Story-Roller E, Galanis C, Parrish N, et al.
Combinations of avibactam and carbapenems exhibit enhanced potencies against drug-resistant Mycobacterium abscessus
. Future Microbiol 2017;12:473-80.
Tatano Y, Yamabe S, Sano C, Tomioka H. Anti-Mycobacterium avium
complex activity of clarithromycin, rifampin, rifabutin, and ethambutol in combination with adenosine 5'-triphosphate. Diagn Microbiol Infect Dis 2017;88:241-6.
Zhang Z, Lu J, Liu M, Wang Y, Zhao Y, Pang Y, et al
. In vitro
activity of clarithromycin in combination with other antimicrobial agents against Mycobacterium abscessus
and Mycobacterium massiliense
. Int J Antimicrob Agents 2017;49:383-6.
Patel YS, Mehra S. Synergistic response of rifampicin with hydroperoxides on Mycobacterium
: A Mechanistic study. Front Microbiol 2017;8:2075.
Moore RE, Millar BC, Panickar JR, Moore JE. Interaction of South Asian spices with conventional antibiotics: Implications for antimicrobial resistance for Mycobacterium abscessus
and cystic fibrosis. Int J Mycobacteriol 2018;7:257-60.
] [Full text]
Olaru AM, Vasilache V, Danac R, Mangalagiu II. Antimycobacterial activity of nitrogen heterocycles derivatives: 7-(pyridine-4-yl)-indolizine derivatives. Part VII8-12. J Enzyme Inhib Med Chem 2017;32:1291-8.
Cannalire R, Machado D, Felicetti T, Santos Costa S, Massari S, Manfroni G, et al.
Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium
. Eur J Med Chem 2017;140:321-30.
Singh AK, Thakare R, Karaulia P, Das S, Soni I, Pandey M, et al.
Biological evaluation of diphenyleneiodonium chloride (DPIC) as a potential drug candidate for treatment of non-tuberculous mycobacterial infections. J Antimicrob Chemother 2017;72:3117-21.
Franz ND, Belardinelli JM, Kaminski MA, Dunn LC, Calado Nogueira de Moura V, Blaha MA, et al.
Design, synthesis and evaluation of indole-2-carboxamides with pan anti-mycobacterial activity. Bioorg Med Chem 2017;25:3746-55.
Yavvari PS, Gupta S, Arora D, Nandicoori VK, Srivastava A, Bajaj A, et al.
Clathrin-independent killing of intracellular mycobacteria and biofilm disruptions using synthetic antimicrobial polymers. Biomacromolecules 2017;18:2024-33.
Compain F, Soroka D, Heym B, Gaillard JL, Herrmann JL, Dorchène D, et al
. In vitro
activity of tedizolid against the Mycobacterium abscessus complex. Diagn Microbiol Infect Dis 2018;90:186-9.
Tang YW, Cheng B, Yeoh SF, Lin RTP, Teo JWP. Tedizolid activity against clinical Mycobacterium abscessus
complex isolates-an in vitro
characterization study. Front Microbiol 2018;9:2095.
Deshpande D, Srivastava S, Pasipanodya JG, Lee PS, Gumbo T. Tedizolid is highly bactericidal in the treatment of pulmonary Mycobacterium avium
complex disease. J Antimicrob Chemother 2017;72:i30-5.
Kanehiro Y, Tomioka H, Pieters J, Tatano Y, Kim H, Iizasa H, et al.
Identification of novel mycobacterial inhibitors against mycobacterial protein kinase G. Front Microbiol 2018;9:1517.
Kim TS, Choe JH, Kim YJ, Yang CS, Kwon HJ, Jeong J, et al.
Activity of LCB01-0371, a novel oxazolidinone, against Mycobacterium abscessus
. Antimicrob Agents Chemother 2017;61. pii: e02752-16.
Deshpande D, Srivastava S, Pasipanodya JG, Gumbo T. Linezolid as treatment for pulmonary Mycobacterium avium
disease. J Antimicrob Chemother 2017;72:i24-9.
Krátký M, Stolaříková J, Vinšová J. Novel sulfamethoxazole ureas and oxalamide as potential antimycobacterial agents. Molecules 2017;22. pii: E535.
Krátký M, Vinšová J, Stolaříková J. Antimicrobial activity of rhodanine-3-acetic acid derivatives. Bioorg Med Chem 2017;25:1839-45.
Guy CS, Tichauer E, Kay GL, Phillips DJ, Bailey TL, Harrison J, et al.
Identification of the anti-mycobacterial functional properties of piperidinol derivatives. Br J Pharmacol 2017;174:2183-93.
Sardari S, Feizi S, Rezayan AH, Azerang P, Shahcheragh SM, Ghavami G, et al.
Synthesis and biological evaluation of thiosemicarbazide derivatives endowed with high activity toward Mycobacterium bovis
. Iran J Pharm Res 2017;16:1128-40.
Rezayan AH, Hariri S, Azerang P, Ghavami G, Portugal I, Sardari S, et al.
Synthesis of novel fluorene bisamide derivatives via Ugi reaction and evaluation their biological activity against Mycobacterium species
. Iran J Pharm Res 2017;16:745-55.
Hans S, Sharma S, Hameed S, Fatima Z. Sesamol exhibits potent antimycobacterial activity: Underlying mechanisms and impact on virulence traits. J Glob Antimicrob Resist 2017;10:228-37.
McDonald RA, Verma D, Vongtongsalee K, Stapleton M, Ordway D, Ahonen MR, et al
. Antibiotic alternative for the treatment of nontuberculosis Mycobacterium
infections. Pediatr Pulmonol 2018;53(S2):290.
Vajs J, Proud C, Brozovic A, Gazvoda M, Lloyd A, Roper DI, et al.
Diaryltriazenes as antibacterial agents against methicillin resistant Staphylococcus aureus
(MRSA) and Mycobacterium smegmatis
. Eur J Med Chem 2017;127:223-34.
Choi SR, Britigan BE, Switzer B, Hoke T, Moran D, Narayanasamy P, et al
. In vitro
efficacy of free and nanoparticle formulations of gallium (III) meso-tetraphenylporphyrine against Mycobacterium avium
and Mycobacterium abscessus
and gallium biodistribution in mice. Mol Pharm 2018;15:1215-25.
Guo ZK, Wang R, Chen FX, Liu TM. Streptoxamine, an unprecedented benzoisoindole-deferoxamine hybrid from the locust-derived streptomyces sp. HKHCa2. Fitoterapia 2018;127:25-8.
Vosátka R, Krátký M, Švarcová M, Janoušek J, Stolaříková J, Madacki J, et al.
New lipophilic isoniazid derivatives and their 1,3,4-oxadiazole analogues: Synthesis, antimycobacterial activity and investigation of their mechanism of action. Eur J Med Chem 2018;151:824-35.
Ramis IB, Figueiredo R, Ramos DF, Halicki PCB, von Groll A, Viveiros M, et al.
Activity of rifabutin and hemi-synthetic derivatives against Mycobacterium abscessus
. Med Chem 2018;14:394-9.
Nguyen PC, Madani A, Santucci P, Martin BP, Paudel RR, Delattre S, et al.
Cyclophostin and cyclipostins analogues, new promising molecules to treat mycobacterial-related diseases. Int J Antimicrob Agents 2018;51:651-4.
Krátký M, Štěpánková Š, Vorčáková K, Navrátilová L, Trejtnar F, Stolaříková J, et al.
Synthesis of readily available fluorophenylalanine derivatives and investigation of their biological activity. Bioorg Chem 2017;71:244-56.
Krátký M, Bősze S, Baranyai Z, Stolaříková J, Vinšová J. Synthesis and biological evolution of hydrazones derived from 4-(trifluoromethyl) benzohydrazide. Bioorg Med Chem Lett 2017;27:5185-9.
Krátký M, Dzurková M, Janoušek J, Konečná K, Trejtnar F, Stolaříková J, et al.
Sulfadiazine salicylaldehyde-based schiff bases: Synthesis, antimicrobial activity and cytotoxicity. Molecules 2017;22. pii: E1573.
Deppisch C, Herrmann G, Graepler-Mainka U, Wirtz H, Heyder S, Engel C, et al.
Gaseous nitric oxide to treat antibiotic resistant bacterial and fungal lung infections in patients with cystic fibrosis: A phase I clinical study. Infection 2016;44:513-20.
Yaacoby-Bianu K, Gur M, Toukan Y, Nir V, Hakim F, Geffen Y, et al.
Compassionate nitric oxide adjuvant treatment of persistent Mycobacterium
infection in cystic fibrosis patients. Pediatr Infect Dis J 2018;37:336-8.
Bogdanovski K, Ghaffari A, da Silva JL, Zelazny AM, Olivier KN. High-dose inhaled nitric oxide as a potential therapy against Mycobacterium abscessus
lung infection in cystic fibrosis. Pediatr Pulmonol 2018;53(S2):99.
Miller CC, McMullin B, Martins J, Quon BS. Inhaled gaseous nitric oxide as a treatment for nontuberculous mycobacteria lung infection study. Pediatr Pulmonol 2018;53(S2):88.
Banaschewski B, Verma D, Stapleton M, Hittinger M, Knoth K, Lehr C, et al
. Development of QRM-003, a novel nebulized antibiotic for the treatment of nontuberculous mycobacterial infections in cystic fibrosis. Pediatr Pulmonol 2018;53(S2):73-4.
Zhang J, Leifer F, Rose S, Chun DY, Thaisz J, Herr T, et al.
Amikacin liposome inhalation suspension (ALIS) penetrates non-tuberculous mycobacterial biofilms and enhances amikacin uptake into macrophages. Front Microbiol 2018;9:915.
Griffith DE, Eagle G, Thomson R, Aksamit TR, Hasegawa N, Morimoto K, et al.
Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium
complex (CONVERT): A Prospective, open-label, randomized study. Am J Respir Crit Care Med 2018. doi: 10.2174/1574891X13666180626170155.
Caimmi D, Martocq N, Trioleyre D, Guinet C, Godreuil S, Daniel T, et al.
Positive effect of liposomal amikacin for inhalation on Mycobacterium abcessus
in cystic fibrosis patients. Open Forum Infect Dis 2018;5:ofy034.
Olivier KN, Griffith DE, Eagle G, McGinnis JP 2nd
, Micioni L, Liu K, et al.
Randomized trial of liposomal amikacin for inhalation in nontuberculous mycobacterial lung disease. Am J Respir Crit Care Med 2017;195:814-23.
Dupont C, Viljoen A, Thomas S, Roquet-Banères F, Herrmann JL, Pethe K, et al.
Bedaquiline inhibits the ATP synthase in Mycobacterium abscessus
and is effective in infected Zebrafish. Antimicrob Agents Chemother 2017;61. pii: e01225-17.
Aguilar-Ayala DA, Cnockaert M, André E, Andries K, Gonzalez-Y-Merchand JA, Vandamme P, et al
. In vitro
activity of bedaquiline against rapidly growing nontuberculous mycobacteria. J Med Microbiol 2017;66:1140-3.
Vesenbeckh S, Schönfeld N, Krieger D, Bettermann G, Bauer TT, Rüssmann H, et al.
Bedaquiline as a potential agent in the treatment of M. intracellulare
and M. avium
infections. Eur Respir J 2017;49. pii: 1601969.
Pang Y, Zheng H, Tan Y, Song Y, Zhao Y.In vitro
activity of bedaquiline against nontuberculous mycobacteria in China. Antimicrob Agents Chemother 2017;61. pii: e02627-16.
Brown-Elliott BA, Philley JV, Griffith DE, Thakkar F, Wallace RJ Jr. In vitro
susceptibility testing of bedaquiline against Mycobacterium avium
complex. Antimicrob Agents Chemother 2017;61. pii: e01798-16.
Li B, Ye M, Guo Q, Zhang Z, Yang S, Ma W, et al.
Determination of MIC distribution and mechanisms of decreased susceptibility to bedaquiline among clinical isolates of Mycobacterium abscessus
. Antimicrob Agents Chemother 2018;62. pii: e00175-18.
Martiniano SL, Wagner BD, Levin A, Nick JA, Sagel SD, Daley CL, et al.
Safety and effectiveness of clofazimine for primary and refractory nontuberculous mycobacterial infection. Chest 2017;152:800-9.
Luo J, Yu X, Jiang G, Fu Y, Huo F, Ma Y, et al
. In vitro
activity of clofazimine against nontuberculous mycobacteria isolated in Beijing, China. Antimicrob Agents Chemother 2018;62. pii: e00072-18.
Aziz DB, Low JL, Wu ML, Gengenbacher M, Teo JWP, Dartois V, et al.
Rifabutin is active against Mycobacterium abscessus
complex. Antimicrob Agents Chemother 2017;61. pii: e00155-17.
Moore JE, Koulianos G, Hardy M, Misawa N, Millar BC. Antimycobacterial activity of veterinary antibiotics (Apramycin and framycetin) against Mycobacterium abscessus
: Implication for patients with cystic fibrosis. Int J Mycobacteriol 2018;7:265-7.
] [Full text]
Kirkwood ZI, Millar BC, Downey DG, Moore JE. Anti-mycobacterial activity of non-antibiotics associated with the polypharmacy of cystic fibrosis against Mycobacterium abscessus
. Int J Mycobacteriol 2018;7:358-60.
] [Full text]
Johnston DN, O'Kane CM. Investigating the effect of zafirlukast on Mycobacterium abscessus
. Ir J Med Sci 2018;187 Suppl 8:S298.
Richard M, Gutiérrez AV, Viljoen A, Rodriguez-Rincon D, Roquet-Baneres F, Blaise M, et al.
Mutations in the MAB_2299c TetR regulator confer cross-resistance to clofazimine and bedaquiline in Mycobacterium abscessus
. Antimicrob Agents Chemother 2018. pii: AAC.01316-18.
Kwofie SK, Dankwa B, Odame EA, Agamah FE, Doe LPA, Teye J, et al. In silico
screening of isocitrate lyase for novel anti-buruli ulcer natural products originating from Africa. Molecules 2018;23. pii: E1550.
Richter A, Strauch A, Chao J, Ko M, Av-Gay Y. Screening of preselected libraries targeting Mycobacterium abscessus
for drug discovery. Antimicrob Agents Chemother 2018;62. pii: e00828-18.
Jeong J, Kim G, Moon C, Kim HJ, Kim TH, Jang J, et al.
Pathogen box screening for hit identification against Mycobacterium abscessus
. PLoS One 2018;13:e0195595.
Low JL, Wu ML, Aziz DB, Laleu B, Dick T. Screening of TB actives for activity against Nontuberculous mycobacteria
delivers high hit rates. Front Microbiol 2017;8:1539.
Sun F, Oh S, Kim J, Kato T, Kim HJ, Lee J, et al.
Enhanced internalization of macromolecular drugs into Mycobacterium smegmatis
with the assistance of silver nanoparticles. J Microbiol Biotechnol 2017;27:1483-90.
Ouertatani-Sakouhi H, Kicka S, Chiriano G, Harrison CF, Hilbi H, Scapozza L, et al.
Inhibitors of Mycobacterium marinum
virulence identified in a Dictyostelium discoideum
host model. PLoS One 2017;12:e0181121.
Kim TS, Shin YH, Lee HM, Kim JK, Choe JH, Jang JC, et al.
Ohmyungsamycins promote antimicrobial responses through autophagy activation via AMP-activated protein kinase pathway. Sci Rep 2017;7:3431.
Bajpai U, Mehta AK, Eniyan K, Sinha A, Ray A, Virdi S, et al.
Isolation and characterization of bacteriophages from India, with lytic activity against Mycobacterium tuberculosis
. Can J Microbiol 2018;64:483-91.
Furfaro LL, Payne MS, Chang BJ. Bacteriophage therapy: Clinical trials and regulatory hurdles. Front Cell Infect Microbiol 2018;8:376.
[Table 1], [Table 2], [Table 3], [Table 4], [Table 5], [Table 6], [Table 7], [Table 8]